2027 Leads Side effects 
Pharmaceutical Technology
DECEMBER 16, 2022
GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.
LEVO Health
JULY 15, 2024
billion by 2027. Given their effectiveness, GLP-1 medications have gained popularity, leading to a surge in market demand. Here’s how: Enhance Patient Engagement Engaging patients effectively is key to building a successful GLP-1 program. In 2021, the GLP-1 market was valued at $16.53
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medico Reach
FEBRUARY 8, 2023
AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. billion by 2027. billion in 2022 and will expand at a CAGR of 10.3%
Pharmaceutical Technology
NOVEMBER 30, 2022
In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Novo Nordisk is another company leading the charge in this field. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Novo Nordisk is another company leading the charge in this field. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.
Expert insights. Personalized for you.
59 
Let's personalize your content